Valuation: Intervacc AB

Market Cap 33Cr 3.3Cr 2.94Cr 2.74Cr 2.49Cr 4.69Cr 317.36Cr 4.73Cr 13Cr 161.97Cr 12Cr 12Cr 520.64Cr P/E 2026 *
-0.87x
P/E 2027 * -0.87x
Enterprise Value 24Cr 2.41Cr 2.15Cr 2Cr 1.82Cr 3.43Cr 232.01Cr 3.46Cr 9.41Cr 118.41Cr 9.04Cr 8.85Cr 380.62Cr EV / Sales 2026 *
11.5x
EV / Sales 2027 * 9x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-3.71%
1 week-2.40%
Current month-7.79%
1 month-15.77%
3 months-29.70%
6 months+8.72%
Current year+1.19%
1 week 0.93
Extreme 0.93
1.04
1 month 0.9
Extreme 0.9
1.11
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
23/02/25 Free

Chief Financial Officer

9,29,208 1.2269%
17/02/25 Buy

Chief Executive Officer

1,35,000 0.1783%
17/02/25 Sell

Chief Executive Officer

2,78,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-3.71%-2.40%-9.05%-74.35% 3.3Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-0.37%-3.88%+19.75%+78.35% 5.74TCr
+1.63%+0.98%+3.83%+38.21% 4.76TCr
+0.50%+2.94%+345.86%+722.17% 4.43TCr
+3.05%-1.80%+29.79%+34.51% 4.25TCr
+1.00%-1.46%+4.97%+111.90% 4.07TCr
-0.54%+2.93%+9.31%+54.06% 3.1TCr
+1.56%+4.53%+31.34%+26.92% 2.85TCr
+0.76%-1.45%-7.15%-11.12% 2.43TCr
Average +0.78%-0.39%+47.80%+107.48% 3.91TCr
Weighted average by Cap. +1.52%-0.84%+58.30%+136.92%

Financials

2026 *2027 *
Net sales 2.1Cr 20.91L 18.65L 17.38L 15.82L 29.78L 20Cr 30.01L 81.7L 10Cr 78.5L 76.81L 33Cr 3Cr 29.87L 26.65L 24.83L 22.59L 42.55L 29Cr 42.86L 1.17Cr 15Cr 1.12Cr 1.1Cr 47Cr
Net income -8.24Cr -82.1L -73.24L -68.24L -62.1L -1.17Cr -79Cr -1.18Cr -3.21Cr -40Cr -3.08Cr -3.02Cr -129.72Cr -8.36Cr -83.3L -74.31L -69.23L -63L -1.19Cr -80Cr -1.2Cr -3.25Cr -41Cr -3.13Cr -3.06Cr -131.6Cr
Net Debt -8.9Cr -88.62L -79.06L -73.66L -67.03L -1.26Cr -85Cr -1.27Cr -3.46Cr -44Cr -3.33Cr -3.26Cr -140.02Cr -6.1Cr -60.74L -54.19L -50.48L -45.94L -86.52L -58Cr -87.16L -2.37Cr -30Cr -2.28Cr -2.23Cr -96Cr
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
05/26/05 SEK 0.9350 -3.71% 2,86,105
02/26/02 SEK 0.9710 -5.73% 5,22,613
01/26/01 SEK 1.030 +1.58% 1,03,130
30/26/30 SEK 1.014 +2.42% 3,09,182
29/26/29 SEK 0.9900 +5.88% 4,84,605

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock